title: Driving ability under sertindole.
abstract: BACKGROUND
  Fitness to drive is an important prerequisite for the functional autonomy and thus also relevant for patients with a psychiatric illness. The efficacy of sertindole in the treatment of positive and negative schizophrenia symptoms has been shown in various studies. However, hitherto there exist no data about patients' fitness to drive under sertindole.
  
  
  METHODS
  A non-randomized clinical study with 30 schizophrenic inpatients receiving sertindole (n=10), risperidone (n=10) or quetiapine (n=10) was conducted. Patients were tested under steady-state plasma level conditions prior to discharge to outpatient treatment. Data were collected with the computerized Act and React Testsystem (ART90) and the Wiener Determinationsgerät (WDG) measuring psychomotor skills relevant for fitness to drive.
  
  
  RESULTS
  The main findings of this study are (i) that about 26% of schizophrenic patients, -following psychopathologic stabilization and prior discharge to outpatient treatment show severe impairments with respect to driving skills. (ii) Statistically significant differences between atypical antipsychotics could neither be demonstrated on the level of the global driving ability score nor on individual functional domains essential for fitness to drive.
  
  
  CONCLUSIONS
  With respect to driving skills no differences have been found between patients treated with sertindole, risperidone or quetia-pine. However, a great proportion of schizophrenic patients partly remitted must be considered as unfit to drive, even when stabilized on treatment with atypical antipsychotics.
authors: kbo Inn-Salzach-Klinikum, Academic Hospital of Psychiatry, Psychotherapy, Psychosomatic Medicine and Neurology, Wasserburg a. Inn, Germany. Alexander.Brunnauer@iskl.de
authors: A
authors: A
authors: Brunnauer
authors: G
authors: G
authors: Laux
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001334:Automobile Driving / Q000523:psychology* / Q000706:statistics & numerical data; D003987:Dibenzothiazepines / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011597:Psychomotor Performance / Q000187:drug effects; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000494:pharmacology / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology; D014796:Visual Perception / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D007093:Imidazoles; D007211:Indoles; D000069348:Quetiapine Fumarate; C066304:sertindole; D018967:Risperidone